Of HDAC inhibitors, SAHA and romidepsin have been approved for CTCL, romidepsin also for PTCL, belinostat for therapy of PTCL and panobinostat for multiple myeloma. Here, HDAC9 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.